A Comprehensive Review: Molecular Target And Procurable Treatment For Rheumatoid Arthritis
Main Article Content
Abstract
Recently licensed synthetic small-molecule-focused anti-rheumatism that adapts to sickness medication is called Tofacitinib. The medication was created to block pro-inflammatory receptor signaling in a precise and selective manner. By blocking the Janus kinases, Tofacitinib limits Inflammation is a distinct process that biological medicines cannot address. Patients with medium-to-serious active Rheumatoid Arthritis now have the option of receiving therapy with Tofacitinib. Numerous clinical studies have demonstrated tofacitinib's effectiveness. The drug stops the radiographic evolution of the illness. One noteworthy aspect of tofacitinib's new mechanism of action is that it offers patients who do not respond to current treatments hope for a successful course of treatment. Rheumatoid arthritis (RA) is a chronic inflammatory disorder that primarily affects joints. The molecular targets for the treatment of RA aim to reduce inflammation, halt disease progression, and manage symptoms these include Tumour Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), Interleukin-1 (IL-1), Interleukin-1 (IL-1), T-cell Co-stimulation. B-cell Depletion, Interleukin-17 (IL-17), Granulocyte-macrophage colony-stimulating factor (GM-CSF), HLA-DRB1, PTPN22, STAT4, PADI4, IL2RA, CTLA4, IRAK1, TNFAIP3, BLK, Potential Therapeutic Approaches, Gene Therapy: Modifying expression or correcting mutations in these genes., Targeted Drugs: Developing drugs that specifically modulate the activity of proteins encoded by these genes, designing biologic agents that interact with the gene products involved in RA pathogenesis.